Cytokinetics, Incorporated (CYTK) Cash Flow Statement

The OCF-to-net-income ratio of 0.65 in 2026Q3 implies that non-cash charges, principally stock-based compensation of $34.7M and other accruals, account for a meaningful portion of the reported loss. The ratio has trended between 0.35 and 0.95 across the ten quarters, which indicates that the cash-versus-accrual gap is volatile rather than structural. Investors should monitor whether this gap narrows as commercial revenue becomes more recurring, since it currently reflects timing of milestone recognition and R&D accruals more than underlying cash efficiency.

The FCF margin reached -198.3% in 2025Q2 and -406.5% in 2024Q2, so the recent -2.6% figure reflects revenue scaling faster than cash burn rather than a true breakeven trajectory. Because quarterly revenue is lumpy and milestone-dependent, the improvement may not persist if a single period lacks partner payments. The business continues to depend on its existing cash position and external funding rather than self-generated free cash flow.

Capital spending has run between 1.5% and 31.8% of revenue, with the higher readings occurring in quarters when revenue was temporarily depressed, which makes the ratio an unreliable efficiency gauge here. D&A of $3.6M against capex of $0.7M suggests the company is not currently reinvesting heavily in productive assets. The cash flow profile is therefore a function of clinical and commercial operating spend, not infrastructure, which warrants monitoring as launch-related investment grows.

The absence of dividends and buybacks is consistent with a company in a cash-consuming development and launch phase, where preserving liquidity takes precedence over distributions. The 2025Q3 $21.3M outflow in the buyback line appears irregular relative to the rest of the series and warrants review in the filings to determine its nature. Shareholder value depends on whether the cash deployed into R&D and launch converts into durable revenue rather than on any current return of capital.